Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

doi:10.1200/JCO.2013.52.2425

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 May 2014

Ribera Josep-Maria, Oriol Albert, Morgades Mireia, Montesinos Pau, Sarrà Josep, González-Campos José, Brunet Salut, Tormo Mar, Fernández-Abellán Pascual, Guàrdia Ramon, Bernal María-Teresa, Esteve Jordi, Barba Pere, Moreno María-José, Bermúdez Arancha, Cladera Antonia, Escoda Lourdes, García-Boyero Raimundo, Del Potro Eloy, Bergua Juan, Amigo María-Luz, Grande Carlos, Rabuñal María-José, Hernández-Rivas Jesús-María, Feliu Evarist

Abstract excerpt

PURPOSE: Minimal residual disease (MRD) is an important prognostic factor in adults with acute lymphoblastic leukemia (ALL) and may be used for treatment decisions. The Programa Español de Tratamientos en Hematología (PETHEMA) ALL-AR-03 trial (Treatment of High Risk Adult Acute Lymphoblastic Leukemia [LAL-AR/2003]) assigned adolescent and adult patients (age 15 to 60 years) with high-risk ALL (HR-ALL) without the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Kaplan-Meier Estimate

Share to Maintenance Chemotherapy

Share to Neoplasm, Residual

Share to Patient Selection

Share to Philadelphia Chromosome

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Proportional Hazards Models

Source

Open in PubMed

Identifiers

PMID: 24752047
DOI: 10.1200/JCO.2013.52.2425

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of the PETHEMA ALL-AR-03 trial.PMID 24752047Read ↗

Importance of measurable residual disease in the outcome of adults with acute lymphoblastic leukemia after allogeneic stem cell transplantation: Long follow-up analysis from a single transplant centerSemantic proximity Read ↗

Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell TransplantationSemantic proximity Read ↗

Prognostic impact of pretreatment cytogenetics in adult P hiladelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual diseaseSemantic proximity Read ↗

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemiaSemantic proximity Read ↗

Treatment and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults after relapse.Semantic proximity Read ↗

Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.Semantic proximity Read ↗

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemiaSemantic proximity Read ↗

The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemiaSemantic proximity Read ↗

MRD in Philadelphia Chromosome-Positive ALL: Methodologies and Clinical ImplicationsSemantic proximity Read ↗

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913Semantic proximity Read ↗

Outcome of Treatment in Children with Philadelphia Chromosome–Positive Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.